Co-Diagnostics to Hold Press Conference
Co-Diagnostics is inviting media, analysts and investors to a CEO-led press conference and webcast on September 16, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Co-Diagnostics (CODX)/b) will host a press conference and live webcast on Wednesday, Sept. 16, 2026, at 10:30 a.m. Eastern Time.The event will take place at W New York – Times Square, 1567 Broadway, New York, NY 10036, with a concurrent webcast available to registered participants. Chief Executive Officer Dwight Egan will deliver a presentation followed by a question-and-answer session for media, analysts and investors.
Details
News Market Reaction – CODX
On Sep 16, the first trading day after this news, CODX closed 17.47% below the previous close. Argus tracked a trough of -22.2% from its starting point during tracking. Our momentum scanner recorded 19 alerts for this stock that day. That session’s volume was 6.1x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Sep 16 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Media, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30 a.m. ET
Co-Diagnostics Press Conference and Live Webcast:
Date: Wednesday, Sept. 16, 2026
Time: 10:30 a.m. ET | 8:30 a.m. MT
Location:
Webcast: Click Here to Register
Co-Diagnostics Chief Executive Officer Dwight Egan, will deliver a presentation followed by a question-and-answer session. Members of the media, analysts, and investors are invited to attend in person or join the live webcast.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-to-hold-press-conference-302879628.html
SOURCE Co-Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who will speak at the Co-Diagnostics press conference and what is the format?
Co-Diagnostics states that Chief Executive Officer Dwight Egan will deliver a presentation. The press conference will be followed by a question-and-answer session for attendees.
How and where can attendees join the Co-Diagnostics press conference?
The press conference is scheduled for Wednesday, Sept. 16, 2026, at 10:30 a.m. ET (8:30 a.m. MT) at W New York – Times Square, 1567 Broadway, New York, NY 10036. Members of the media, analysts and investors may attend in person or join via a live webcast after completing the provided registration link.